AU8065294A - Receptor on the surface of activated t-cells: acts-4 - Google Patents

Receptor on the surface of activated t-cells: acts-4

Info

Publication number
AU8065294A
AU8065294A AU80652/94A AU8065294A AU8065294A AU 8065294 A AU8065294 A AU 8065294A AU 80652/94 A AU80652/94 A AU 80652/94A AU 8065294 A AU8065294 A AU 8065294A AU 8065294 A AU8065294 A AU 8065294A
Authority
AU
Australia
Prior art keywords
act
antibody
polypeptide
cells
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU80652/94A
Other languages
English (en)
Inventor
David William Buck
Edgar George Engleman
Wayne Godfrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Leland Stanford Junior University
Original Assignee
Becton Dickinson and Co
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson and Co, Leland Stanford Junior University filed Critical Becton Dickinson and Co
Publication of AU8065294A publication Critical patent/AU8065294A/en
Priority to AU94138/98A priority Critical patent/AU9413898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70514CD4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493Immunosupressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
AU80652/94A 1993-11-03 1994-11-03 Receptor on the surface of activated t-cells: acts-4 Abandoned AU8065294A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU94138/98A AU9413898A (en) 1993-11-03 1998-11-26 Receptor on the surface of activated T-cells: ACTS-4

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US147784 1993-11-03
US08/147,784 US5821332A (en) 1993-11-03 1993-11-03 Receptor on the surface of activated CD4+ T-cells: ACT-4
PCT/GB1994/002415 WO1995012673A1 (en) 1993-11-03 1994-11-03 Receptor on the surface of activated t-cells: acts-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU94138/98A Division AU9413898A (en) 1993-11-03 1998-11-26 Receptor on the surface of activated T-cells: ACTS-4

Publications (1)

Publication Number Publication Date
AU8065294A true AU8065294A (en) 1995-05-23

Family

ID=22522890

Family Applications (5)

Application Number Title Priority Date Filing Date
AU80652/94A Abandoned AU8065294A (en) 1993-11-03 1994-11-03 Receptor on the surface of activated t-cells: acts-4
AU94138/98A Abandoned AU9413898A (en) 1993-11-03 1998-11-26 Receptor on the surface of activated T-cells: ACTS-4
AU23233/01A Ceased AU781998B2 (en) 1993-11-03 2001-02-26 Receptor on the surface of activated T-cells: ACTS-4
AU2005202316A Ceased AU2005202316B2 (en) 1993-11-03 2005-05-27 Receptor on the surface of activated T-cells- ACT-4
AU2009248426A Abandoned AU2009248426A1 (en) 1993-11-03 2009-12-10 Receptor on the surface of activated T-cells- ACT-4

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU94138/98A Abandoned AU9413898A (en) 1993-11-03 1998-11-26 Receptor on the surface of activated T-cells: ACTS-4
AU23233/01A Ceased AU781998B2 (en) 1993-11-03 2001-02-26 Receptor on the surface of activated T-cells: ACTS-4
AU2005202316A Ceased AU2005202316B2 (en) 1993-11-03 2005-05-27 Receptor on the surface of activated T-cells- ACT-4
AU2009248426A Abandoned AU2009248426A1 (en) 1993-11-03 2009-12-10 Receptor on the surface of activated T-cells- ACT-4

Country Status (12)

Country Link
US (6) US5821332A (de)
EP (1) EP0726952B1 (de)
JP (3) JPH09504693A (de)
AT (1) ATE350475T1 (de)
AU (5) AU8065294A (de)
CA (1) CA2175577C (de)
DE (1) DE69434908T2 (de)
DK (1) DK0726952T3 (de)
ES (1) ES2281072T3 (de)
HK (1) HK1001464A1 (de)
PT (1) PT726952E (de)
WO (1) WO1995012673A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782568B2 (en) * 1994-02-04 2005-08-11 Arthur Allen Vandenbark T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions II
AU784729B2 (en) * 1994-02-10 2006-06-01 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
AU781082B2 (en) * 1994-02-04 2005-05-05 Arthur Allen Vandenbark T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions I
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US20020025551A1 (en) * 1998-04-09 2002-02-28 Millennium Pharmaceuticals, Inc., A Delaware Corporation Novel molecules of the t129-related protein family and uses thereof
WO1999024554A2 (en) 1997-11-12 1999-05-20 University Of Pittsburgh Isolation, characterization, and identification of dendritic like cells and methods of using same
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
GB9916703D0 (en) 1999-07-16 1999-09-15 Alcami Antonio Viral protein binding compositions and methods
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (de) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antikörper gegen ctla4(cd152), sie enthaltende konjugate und ihre verwendung
WO2003009861A1 (en) * 2001-07-24 2003-02-06 Genset S.A. Agonists and antagonists of metabolix in the treatment of metabolic disorders
GB0123276D0 (en) 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
EP1525223B1 (de) * 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
EP2364716A3 (de) * 2002-11-08 2012-01-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Erkrankungen im Zusammenhang mit natürlichen Killerzellen
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2605380T3 (es) 2005-05-06 2017-03-14 Providence Health & Services - Oregon Proteina de fusión OX40-inmunoglobulina trimérica y métodos de uso
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類cd134(ox40)之人類單株抗體及其製造及使用方法
CA2630157C (en) 2005-12-07 2018-01-09 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
CN101374865A (zh) 2005-12-16 2009-02-25 健泰科生物技术公司 抗ox40l抗体及其使用方法
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック, インコーポレイテッド 抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
AU2010216152B2 (en) * 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2012042480A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CA2863818A1 (en) 2012-02-06 2013-08-15 Brendan CURTI Cancer treatment and monitoring methods using ox40 agonists
EP2925350B1 (de) 2012-12-03 2019-01-30 Bristol-Myers Squibb Company Verbesserung der antikrebswirkung von immunmodulatorischen fc-fusionsproteinen
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
SG10201808746QA (en) 2014-04-03 2018-11-29 Augusta University Research Institute Inc Methods for enhancing the efficacy of a tumor-directed immune response
US20190194654A1 (en) 2014-10-24 2019-06-27 Astrazeneca Ab Combination
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
MX2017013321A (es) 2015-04-22 2018-07-06 Curevac Ag Composicion que contiene arn para tratamiento de enfermedades tumorales.
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN115746143A (zh) 2015-10-02 2023-03-07 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
EP3494139B1 (de) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
EP3500295A2 (de) 2016-08-19 2019-06-26 CureVac AG Rna zur krebstherapie
EP3532094A1 (de) 2016-10-26 2019-09-04 CureVac AG Mrna-impfstoffe mit lipidnanoteilchen
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
KR20190104048A (ko) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
US11819517B2 (en) 2017-06-05 2023-11-21 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
WO2019089921A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
MX2020004967A (es) 2017-11-17 2020-08-27 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
JP2021509586A (ja) 2018-01-08 2021-04-01 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍抗原特異的t細胞について濃縮されたtil製品を生成するためのプロセス
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
WO2019183551A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
AU2019257749A1 (en) 2018-04-27 2020-10-22 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
EP3852524B1 (de) 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion von tils aus kryokonservierten tumorproben
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3118616A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
CN113272421A (zh) 2018-11-05 2021-08-17 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
WO2020205662A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Inc. Ex vivo methods for producing a t cell therapeutic and related compositions and methods
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
EP4037693A1 (de) 2019-09-30 2022-08-10 Astrazeneca AB Kombinationsbehandlung für krebs
US20220389381A1 (en) 2019-10-25 2022-12-08 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
WO2021118990A1 (en) 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CA3172902A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
EP4146793A1 (de) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Auswahl von verbesserten tumorreaktiven t-zellen
TW202208617A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
JP2023538955A (ja) 2020-08-31 2023-09-12 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在シグネチャーおよび免疫療法
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス,インコーポレイテッド 腫瘍浸潤リンパ球療法によるnsclc患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4259164A1 (de) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit braf-hemmern und/oder mek-hemmern
CA3202473A1 (en) 2020-12-17 2022-06-23 Friedrich Graf Finckenstein Treatment of cancers with tumor infiltrating lymphocytes
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody preparations and methods of using them
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル-マイヤーズ スクイブ カンパニー Pd1/pd-l1抗体の皮下投与
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
JP2024515189A (ja) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス,インコーポレイテッド 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2033347C (en) * 1989-06-02 2000-02-29 James E. Hildreth Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
WO1992011870A1 (en) * 1991-01-11 1992-07-23 Repligen Corporation Method of preventing inflammatory damage
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
DK129594A (da) 1994-11-11 1996-05-12 Smidth & Co As F L Fremgangsmåde til fremstilling af klinker i stationær brændingsreaktor
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782568B2 (en) * 1994-02-04 2005-08-11 Arthur Allen Vandenbark T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions II
AU784729B2 (en) * 1994-02-10 2006-06-01 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells

Also Published As

Publication number Publication date
US20040265866A1 (en) 2004-12-30
JPH09504693A (ja) 1997-05-13
ES2281072T3 (es) 2007-09-16
DE69434908D1 (de) 2007-02-15
EP0726952A1 (de) 1996-08-21
US20070077247A1 (en) 2007-04-05
AU781998B2 (en) 2005-06-23
US7364733B2 (en) 2008-04-29
JP2007089585A (ja) 2007-04-12
US20040136995A1 (en) 2004-07-15
AU9413898A (en) 1999-02-18
AU2005202316A1 (en) 2005-06-23
HK1001464A1 (en) 1998-06-19
CA2175577C (en) 2008-09-02
PT726952E (pt) 2007-04-30
AU2323301A (en) 2001-10-04
WO1995012673A1 (en) 1995-05-11
DK0726952T3 (da) 2007-05-14
AU2005202316B2 (en) 2010-01-07
US5821332A (en) 1998-10-13
US6277962B1 (en) 2001-08-21
ATE350475T1 (de) 2007-01-15
AU2009248426A1 (en) 2010-01-07
US20010044522A1 (en) 2001-11-22
EP0726952B1 (de) 2007-01-03
JP2009240311A (ja) 2009-10-22
DE69434908T2 (de) 2007-11-15
CA2175577A1 (en) 1995-05-11

Similar Documents

Publication Publication Date Title
EP0726952B1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
US6242566B1 (en) Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
CA2525499C (en) Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells
AU784729B2 (en) Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
AU1843699A (en) Ligand (ACT-4-L) to a receptor on the surface of activated CD4+T-cells